Discounted Cash Flow (DCF) Analysis Levered
Enzo Biochem, Inc. (ENZ)
$1.3932
+0.00 (+0.23%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 104.71 | 81.17 | 76.02 | 117.73 | 107.07 | 111.62 | 116.36 | 121.30 | 126.45 | 131.82 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -2.73 | 4.81 | -17.18 | 0.39 | -16.59 | -7.69 | -8.02 | -8.36 | -8.71 | -9.08 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -1.89 | -8.13 | -2.17 | -4.44 | -3.47 | -4.84 | -5.05 | -5.26 | -5.48 | -5.72 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -4.62 | -3.32 | -19.35 | -4.05 | -20.06 | -12.53 | -13.06 | -13.62 | -14.20 | -14.80 |
Weighted Average Cost Of Capital
| Share price | $ 1.3,932 |
|---|---|
| Beta | 0.950 |
| Diluted Shares Outstanding | 48.59 |
| Cost of Debt | |
| Tax Rate | -23.64 |
| After-tax Cost of Debt | 0.77% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 8.956 |
| Total Debt | 20.59 |
| Total Equity | 67.70 |
| Total Capital | 88.29 |
| Debt Weighting | 23.32 |
| Equity Weighting | 76.68 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 104.71 | 81.17 | 76.02 | 117.73 | 107.07 | 111.62 | 116.36 | 121.30 | 126.45 | 131.82 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.73 | 4.81 | -17.18 | 0.39 | -16.59 | -7.69 | -8.02 | -8.36 | -8.71 | -9.08 |
| Capital Expenditure | -1.89 | -8.13 | -2.17 | -4.44 | -3.47 | -4.84 | -5.05 | -5.26 | -5.48 | -5.72 |
| Free Cash Flow | -4.62 | -3.32 | -19.35 | -4.05 | -20.06 | -12.53 | -13.06 | -13.62 | -14.20 | -14.80 |
| WACC | ||||||||||
| PV LFCF | -11.71 | -11.40 | -11.10 | -10.81 | -10.53 | |||||
| SUM PV LFCF | -55.54 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 7.05 |
| Free cash flow (t + 1) | -15.09 |
| Terminal Value | -298.91 |
| Present Value of Terminal Value | -212.62 |
Intrinsic Value
| Enterprise Value | -268.16 |
|---|---|
| Net Debt | -1.02 |
| Equity Value | -267.15 |
| Shares Outstanding | 48.59 |
| Equity Value Per Share | -5.50 |